Skip to NavigationSkip to content

non small cell lung cancer

European approval for Pfizer's Vizimpro in first-line non-small cell lung cancer

The European Commission has awarded marketing approval to Pfizer’s tyrosine kinase inhibitor (TKI) Vizimpro (dacomitinib), it has emerged, as a first-line monotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.

Data derived from a Phase 3 study examining the drugs’ use in 227 patients with EGFR-mutated metastatic NSCLC showed a “statistically significant improvement” in progression-free survival, as determined by Independent Radiologic Central (IRC) review, meeting the primary endpoint.

MSD’s Keytruda impresses in lung cancer chemotherapy trial

Keytruda image

MSD’s Keytruda significantly improved overall survival (OS) compared to chemotherapy in people with lung cancer and PD-L1 expression, a trial has found.

In the Phase II/III KEYNOTE-010 trial, Keytruda (pembrolizumab), improved overall survival compared to chemotherapy with docetaxel. 

The study is the first study of its kind to evaluate the potential of an immunotherapy compared to chemotherapy that is based on the prospective measurement of PD-L1 expression in patients with advanced non-small cell lung cancer (NSCLC), whose tumours expressed the PD-L1 gene.  

NICE rejects BMS cancer drug in draft guidance

NHS sign
NICE says Opdivo cannot be considered a cost-effective use of NHS money

In draft guidance, NICE has chosen not to recommend Bristol-Myers Squibb’s Opdivo for the treatment of locally advanced or metastatic squamous non-small-cell lung cancer after prior chemotherapy in adults. 

While the NICE Committee recognised the clinical efficacy of Opdivo (nivolumab) in previously-treated squamous non-small-cell lung cancer (NSCLC), as well as its innovative nature and the fact that the drug met the criteria to be considered a life-extending, end-of-life treatment, the Institute did not consider it a cost-effective use of NHS resources.

Early UK access for AstraZeneca lung cancer drug


UK patients will be among the first in Europe to have free access to AstraZeneca’s cancer drug osimertinib, after the British firm successfully applied to make the drug available through the Early Access to Medicines Scheme.

The drug has been made available for patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer, through the MHRA-led scheme, which provides access to innovative medicines that have not yet been assessed by NICE.

Lung cancer market to hit $10.9bn by 2021

lung cancer x ray

The global market value for non-small cell lung cancer treatment will rise from $6.9 billion in 2014 to $10.9 billion by 2021, new industry figures show.

An analysis by market intelligence firm GBI Research has found the non-small cell lung cancer (NSCLC) market will achieve a compound annual growth rate of 8.5%. The growth will mostly driven by growth across in the US, Canada, UK, Germany, France, Italy, Spain and Japan.

Bristol-Myers Squibb launches Opdivo in the UK for lung cancer

NICE now has to assess Opdivo before it can become available for patients

The immuno-oncology drug Opdivo is available in the UK for people with lung cancer, after Bristol-Myers Squibb launched the drug in its second indication.

BMS adds lung cancer to advanced melanoma in the list of conditions for which the drug is available, after its launch as a treatment for locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) preceding chemotherapy in adults.

No magic bullet, but a growing arsenal against lung cancer

Published on 23/02/11 at 10:57am
Ben Adams
Lung cancer cells
Coloured scanning electron micrograph (SEM) of a lung cancer cell during cell division (cytokinesis)

A man in his 70s is waiting for his appointment with the oncologist after being referred there by his family doctor.

He has been coughing up blood for the last three months and has realised that it isn’t getting any better. He’s been a smoker since he was a teenager, and goes through a pack of 20 cigarettes a day. He’s had the scans, the biopsy and the blood tests, and now the oncologist is about to tell him he has lung cancer. The prognosis is bad, and the man probably won’t see out the year.

Blood clot fears halt cancer trial enrolment

Lilly and BMS have stopped enrolment in a phase III trial of necitumumab, a new treatment for non-small cell lung cancer.

New enrolment to the INSPIRE trial was stopped after an independent Data Monitoring Committee (DMC) detected a raised risk of blood clots in patients receiving the drug.

Novartis drops late stage lung cancer candidate

Novartis' Swiss headquarters
Halting AS404's lung cancer trial will cost Novartis $120 million

Novartis has discontinued phase III trials for its lung cancer candidate ASA404 after it once again failed to meet its primary endpoint.

ASA404 was being tested in squamous and non-squamous non-small cell lung cancer (NSCLC) but failed to meet its primary endpoint of extending survival for the second line treatment of the disease.            

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches